AAPL 142.95 +0.03 (+0.02%)MSFT 232.69 +3.16 (+1.38%)FB 282.93 +4.92 (+1.77%)ZNGA 10.405 +0.085 (+0.82%)NVDA 536.807 -9.3232 (-1.71%)WBA 48.85 +1.03 (+2.15%)GOOG 1921.8 +22.4 (+1.18%)PIH 2.98 -0.01 (-0.33%)
AAPL 142.95 +0.03 (+0.02%)MSFT 232.69 +3.16 (+1.38%)FB 282.93 +4.92 (+1.77%)ZNGA 10.405 +0.085 (+0.82%)NVDA 536.807 -9.3232 (-1.71%)WBA 48.85 +1.03 (+2.15%)GOOG 1921.8 +22.4 (+1.18%)PIH 2.98 -0.01 (-0.33%)

Financial Summary ACOR Quote Acorda Ther

Acorda Therapeutics Inc Quote

Acorda Therapeu (ACOR)

7.52 0.08 Healthcare
Stock Performance rating :
Recommendation :
Not Available
Symbol ACOR
Price 7.52
Beta 1.28
Vol Avg 1.23 M
Mkt cap 71.31 M
Shares 45
Last Div Not Available
Div Yield 0.00%
DCF Unlevered Not Available Not Available
DCF Levered Not Available Not Available
ROE Not Available Not Available
ROA Not Available Not Available
Operating Margin Not Available Not Available
Debt/Equity Not Available Not Available
P/E Not Available Not Available
P/B Not Available Not Available
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 401 493 520 0 0
COGS 81 93 108 136 99
GrossProfit 321 400 411 453 372
Depreciation (included in COGS) 8 15 22 0 0
StockBasedCompe (included in COGS) 29 33 36 33 21
ResearchAndDeve 73 149 203 166 106
SalesGeneralAnd 202 206 235 182 172
OperatingIncome 43 34 -36 64 38
InterestExpense 9 15 17 19 22
OtherIncome -6 1 10 -297 4
IncomeBeforeTax 28 19 -42 -252 20
ProvisionForInc 0 0 0 0 0
NetIncome 18 11 -35 -223 34
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 182 153 159 307 294
ShortTermInvest 125 200 0 0 152
Cash 308 353 159 0 0
AccountReceivab 32 31 52 0 0
Inventories 27 36 43 0 0
DeferredIncomeT 0 2 4 0 0
OtherCurrentAss 9 14 6 2 11
TotalCurrentAss 409 451 273 442 528
PPE 60 66 74 87 117
AccumulatedDepr -14 -26 -40 -50 -57
NetPPE 46 40 34 37 61
EquityAndOtherI 0 0 0 0 0
Goodwill 183 184 281 287 282
IntangibleAsset 433 431 742 431 429
OtherLTAssets 10 8 8 2 0
TotalNonCurrent 672 665 1,070 756 772
TotalAssets 1,081 1,116 1,342 1,198 1,300
ShortTermDebt 1 1 1 0 0
AccountsPayable 20 17 30 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 41 49 84 0 0
DeferredRevenue 38 9 9 9 0
OtherCurrentLia 14 14 24 20 36
TotalCurrentLia 114 91 148 144 140
Debt 290 297 299 0 0
DeferredTaxesLi 24 12 93 22 7
DeferredRevenue 51 42 32 23 0
OtherLTLiabilit 62 72 106 179 221
TotalNonCurrent 426 423 530 534 547
TotalLiabilitie 540 513 678 678 688
CommonStock 0 0 0 0 0
AdditionalPaidI 761 813 921 969 1,005
RetainedEarning -220 -209 -244 -455 -394
AccumulatedOthe 0 0 -13 7 3
TotalStockholde 540 603 664 520 612
TotalLiabilitie 1,081 1,116 1,342 1,198 1,300
Cash Flow Statement
Year 20142015201620172018
NetIncome 18 11 -35 -223 34
Depreciation 8 15 22 0 0
DeferredIncomeT 7 4 -11 -54 -15
StockBasedCompe 29 33 36 33 21
AccountsReceiva -1 1 -20 -29 58
InventoryCS -1 -10 -7 6 8
AccountsPayable 13 -1 38 -4 -3
OtherWorkingCap -11 -14 -3 -3 0
OtherNonCashIte 7 -3 8 48 53
NetCashProvided 75 38 35 96 151
InvestmentsInPP -5 -6 -6 -14 -33
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve -580 -435 -40 0 -249
SalesMaturities 770 356 240 0 98
PurchasesOfInta -479 -1 -267 -1 -1
OtherInvestingA 0 0 0 0 0
NetCashUsedForI -294 -85 -74 -11 -177
DebtIssued 345 0 0 0 0
DebtRepayment 0 0 0 -2 -1
CommonStockIssu 16 18 76 10 15
CommonStockRepu 0 0 0 0 -2
DividendPaid 0 0 0 0 0
OtherFinancingA -8 -1 -30 54 0
NetCashProvided 353 18 46 62 13
NetChangeInCash 134 -29 5 149 -14
CashAtBeginning 48 182 153 159 308
CashAtEndOfPeri 182 153 159 307 294
Retained Earnings
Year 20142015201620172018
RetainedEarning ----220-209
NetIncome --1811-35
StockDividend --202-2270
DividendPaid -----
RetainedEarning ---220-209-244
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE ---4640
DeprAnnual 0--14-12-14
CapitalExpendit 004847274
NetPPE --464034
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0--616615
Amortization 0-6-3-8
NewPurchases 0-6102416
intAndGW --6166151,023
Company Profile

CEO

Dr. Ron Cohen

Sector

Healthcare

Industry

Biotechnology

Exchange

Nasdaq Global Select

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.